PE20060739A1 - FORMAS CRISTALINAS DE 3-(1-HIDROXI-1-METIL-ETIL)-1-(4-METOXI-FENIL)-6-[4-(2-OXO-2H-PIRIDIN-1-IL)-FENIL]-1,4,5,6-TETRAHIDRO-PIRAZOLO[3,4-c]PIRIDIN-7-ONA COMO INHIBIDORES DEL FACTOR Xa - Google Patents

FORMAS CRISTALINAS DE 3-(1-HIDROXI-1-METIL-ETIL)-1-(4-METOXI-FENIL)-6-[4-(2-OXO-2H-PIRIDIN-1-IL)-FENIL]-1,4,5,6-TETRAHIDRO-PIRAZOLO[3,4-c]PIRIDIN-7-ONA COMO INHIBIDORES DEL FACTOR Xa

Info

Publication number
PE20060739A1
PE20060739A1 PE2005001450A PE2005001450A PE20060739A1 PE 20060739 A1 PE20060739 A1 PE 20060739A1 PE 2005001450 A PE2005001450 A PE 2005001450A PE 2005001450 A PE2005001450 A PE 2005001450A PE 20060739 A1 PE20060739 A1 PE 20060739A1
Authority
PE
Peru
Prior art keywords
pyridin
phenyl
crystalline forms
ona
pyrazolo
Prior art date
Application number
PE2005001450A
Other languages
English (en)
Spanish (es)
Inventor
Michael J Orwat
Mary F Malley
Roxana Schlam
Bing-Shiou Yang
Victor W Rosso
Steven R Fabian
Original Assignee
Bristol Myers Squibb Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bristol Myers Squibb Co filed Critical Bristol Myers Squibb Co
Publication of PE20060739A1 publication Critical patent/PE20060739A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pulmonology (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
PE2005001450A 2004-12-15 2005-12-14 FORMAS CRISTALINAS DE 3-(1-HIDROXI-1-METIL-ETIL)-1-(4-METOXI-FENIL)-6-[4-(2-OXO-2H-PIRIDIN-1-IL)-FENIL]-1,4,5,6-TETRAHIDRO-PIRAZOLO[3,4-c]PIRIDIN-7-ONA COMO INHIBIDORES DEL FACTOR Xa PE20060739A1 (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US63638704P 2004-12-15 2004-12-15
US73798505P 2005-11-18 2005-11-18

Publications (1)

Publication Number Publication Date
PE20060739A1 true PE20060739A1 (es) 2006-08-16

Family

ID=36384503

Family Applications (1)

Application Number Title Priority Date Filing Date
PE2005001450A PE20060739A1 (es) 2004-12-15 2005-12-14 FORMAS CRISTALINAS DE 3-(1-HIDROXI-1-METIL-ETIL)-1-(4-METOXI-FENIL)-6-[4-(2-OXO-2H-PIRIDIN-1-IL)-FENIL]-1,4,5,6-TETRAHIDRO-PIRAZOLO[3,4-c]PIRIDIN-7-ONA COMO INHIBIDORES DEL FACTOR Xa

Country Status (15)

Country Link
US (2) US7371864B2 (cg-RX-API-DMAC7.html)
EP (1) EP1828187A2 (cg-RX-API-DMAC7.html)
JP (1) JP2008524228A (cg-RX-API-DMAC7.html)
KR (1) KR20070087606A (cg-RX-API-DMAC7.html)
AR (1) AR053990A1 (cg-RX-API-DMAC7.html)
AU (1) AU2005317158A1 (cg-RX-API-DMAC7.html)
BR (1) BRPI0519331A2 (cg-RX-API-DMAC7.html)
CA (1) CA2589886A1 (cg-RX-API-DMAC7.html)
IL (1) IL183825A0 (cg-RX-API-DMAC7.html)
MX (1) MX2007006919A (cg-RX-API-DMAC7.html)
NO (1) NO20072666L (cg-RX-API-DMAC7.html)
PE (1) PE20060739A1 (cg-RX-API-DMAC7.html)
RU (1) RU2007126770A (cg-RX-API-DMAC7.html)
TW (1) TW200634011A (cg-RX-API-DMAC7.html)
WO (1) WO2006065853A2 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5588970B2 (ja) 2008-05-27 2014-09-10 ダコ・デンマーク・エー/エス ハイブリダイゼーション組成物及び方法
US9303287B2 (en) * 2009-02-26 2016-04-05 Dako Denmark A/S Compositions and methods for RNA hybridization applications
WO2013046033A1 (en) 2011-09-30 2013-04-04 Dako Denmark A/S Hybridization compositions and methods using formamide
EP3252173A1 (en) 2011-10-21 2017-12-06 Dako Denmark A/S Hybridization compositions and methods
UY38438A (es) 2018-11-02 2020-05-29 Biocryst Pharm Inc Sales cristalinas de un inhibidor de calicreína plasmática

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2002341693B2 (en) * 2001-09-21 2008-05-29 Bristol-Myers Squibb Holdings Ireland Unlimited Company Lactam-containing compounds and derivatives thereof as factor Xa inhibitors
TWI320039B (en) 2001-09-21 2010-02-01 Lactam-containing compounds and derivatives thereof as factor xa inhibitors
US20060069260A1 (en) * 2004-09-28 2006-03-30 Huiping Zhang Preparation of N-aryl pyridones
US7304157B2 (en) * 2004-09-28 2007-12-04 Bristol-Myers Squibb Company Efficient synthesis of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones
US7388096B2 (en) * 2004-09-28 2008-06-17 Bristol-Myers Squibb Company Crystalline forms of a factor Xa inhibitor
US20060069085A1 (en) * 2004-09-28 2006-03-30 Rulin Zhao Preparation of 4,5-dihydro-pyrazolo[3,4-c]pyrid-2-ones

Also Published As

Publication number Publication date
NO20072666L (no) 2007-09-07
JP2008524228A (ja) 2008-07-10
MX2007006919A (es) 2007-06-26
IL183825A0 (en) 2007-09-20
EP1828187A2 (en) 2007-09-05
BRPI0519331A2 (pt) 2009-01-20
WO2006065853A2 (en) 2006-06-22
TW200634011A (en) 2006-10-01
US20060148846A1 (en) 2006-07-06
CA2589886A1 (en) 2006-06-22
US7371864B2 (en) 2008-05-13
US20080188517A1 (en) 2008-08-07
WO2006065853A3 (en) 2006-08-24
RU2007126770A (ru) 2009-01-27
AU2005317158A1 (en) 2006-06-22
AR053990A1 (es) 2007-05-30
KR20070087606A (ko) 2007-08-28

Similar Documents

Publication Publication Date Title
NO20082026L (no) Deazapuriner som er nyttige som inhibitorer for Janus-kinaser
PE20141197A1 (es) INHIBIDORES DE mTOR CINASA PARA INDICADORES DE ONCOLOGIA Y ENFERMEDADES ASOCIADAS CON LA TRAYECTORIA mTOR/PI3K/AKT
NO20083501L (no) Azaindoler som er anvendelige som inhibitorer for Janus-kinaser
NO20084502L (no) Tetrahydropyrrolopyrimidinedioner og deres anvendelse som humane neutrofil elastase inhibitorer
NO20084912L (no) Bisykliske derivater som CETP-inhibitorer
WO2006014665A3 (en) Arylpyrrolidine derivatives as nk-1/ssri antagonists
NI201600166A (es) Compuestos de imidazo[4, 5-c]quinolin-2-ona y su uso para tratar cáncer
MY155418A (en) Dioxa-bicyclo[3.2.1]octane-2,3,4-triol derivatives
WO2007143434A3 (en) Indazole and isoindole derivatives as glucokinase activating agents
CY1123426T1 (el) Μεθοδος για τη ληψη κρυσταλλων αλατος μεγλουμινης του 1-(5,6-διχλωρο-1η-βενζο[d]ιμιδαζολ-2-υλο)-1η-πυραζολο-4-καρβοξυλικου οξεος
UA115228C2 (uk) Інгібітори протеїнкіназ (варіанти), їх застосування для лікування онкологічних захворювань та фармацевтична композиція на їх основі
NO20076447L (no) Bicykliske derivater som modulatorer av ionekanaler
NI201100063A (es) Inhibidores de las enzimas de proteína cinasa activadas por mitógeno p38.
NO20065727L (no) Pyrrolinhibitorer av erk-proteinkinase, syntese derav og deres mellomprodukter
MX2009008253A (es) Derivados de 2-aminopiridina utiles como inhibidores de cinasa.
MX2012008911A (es) Sales y polimorfos de 8-fluoro-2-{4-[(metilamino)metil]fenil}-1,3, 4,5-tetrahidro-6h-acepino[5,4,3-cd]indol-6-ona.
EA201000702A1 (ru) Некоторые производные 2-пиразинона и их применение в качестве ингибиторов нейтрофильной эластазы
ATE497961T1 (de) Als proteinkinaseinhibitoren geeignete verbindungen
WO2008116139A3 (en) N-heterocyclic compounds useful as inhibitors of janus kinases
EA200901138A1 (ru) Производные дианилинопиримидина как ингибиторы киназы wee1, фармацевтическая композиция и применение
NO20085135L (no) Selektive inhibitorer av ROCK-proteinkinase og anvendelse derav
UY31493A1 (es) Derivados de amidas del acido 6,7-dihidro-5h-imidazo[1,2-a]imidazol-3-carboxilico
CL2008002291A1 (es) Compuestos derivados del acido 4-fluor-benzoico, inhibidores de la polimerasa hcv, composicion farmaceutica, kit farmaceutico y su uso para el tratamiento de una infeccion viral por hepatitis c.
EA201170722A1 (ru) Лактамы в качестве ингибиторов бета-секретазы
IL205696A0 (en) Heterocyclic derivatives, compositions comprising the same and uses thereof

Legal Events

Date Code Title Description
FC Refusal